The California Supreme Court has ruled decisively in favour of Gilead Sciences, ending negligence litigation brought by an estimated 24,000 patients over the company’s two-decade-old decision to discontinue development of an alternative HIV treatment.
Monday’s 6-1 decision in Gilead Tenofovir Cases reverses a 2024 California Court of Appeal ruling, resolving whether drugmakers owe patients a duty to pursue safer alternatives once a product already meets FDA approval standards.
Writing for the majority, Justice Joshua Groban held that recognising liability for a manufacturer’s failure to bring a different drug to market sooner would impose burdens capable of undermining pharmaceutical innovation and patient safety more broadly.
The claims centred on Gilead’s drugs formulated with tenofovir disoproxil fumarate, approved by the FDA in 2001, and the company’s 2004 decision to halt work on a successor compound, tenofovir alafenamide fumarate, after concluding the safety gain did not justify further investment.
Justice Kelli Evans dissented, describing Gilead’s conduct as morally blameworthy and calling on the state legislature to reconsider the industry’s existing exemptions from strict liability.
Litigators pursuing product liability claims against pharmaceutical manufacturers now face a narrower set of theories in California, with the ruling foreclosing arguments that a company’s commercial timeline for a follow-on product can itself constitute actionable negligence.
The case drew sustained attention from the defence bar during its pendency: Winston & Strawn tracked the litigation closely through the amicus process, noting that dozens of filers urged the court against recognising a duty to innovate on the basis that it would restrict manufacturers’ ability to manage staged product launches responsibly.
The decision carries weight beyond HIV treatment, given that similar duty-to-innovate theories have surfaced in personal injury claims against manufacturers across the pharmaceutical sector wherever successive product generations are common..
Defence-side practitioners, including firms such as Winston & Strawn that tracked the case through the amicus process, are likely to cite the ruling as persuasive authority in other states where comparable claims remain pending, while plaintiffs’ firms will need to recalibrate how they frame allegations against manufacturers that shelve alternative compounds in favour of an already-marketed product.
Gilead’s win at the California Supreme Court is expected to shape how in-house pharmaceutical counsel structure risk assessments for discontinuing development of alternative compounds, and Evans’s dissent gives plaintiffs’ firms a concrete legislative target to pursue in Sacramento.